Viral clearance (VC) is essential to the viral safety of biologics, and the strategy behind it evolves across the development lifecycle. This session covers the rationale, requirements, and execution of VC studies, compares early- and late-stage scopes, shares early experience with ICH Q5A(R2) and prior knowledge, and addresses the special case of gene therapy products.

This VC seminar is delivered in collaboration with Life Sciences Queensland (LSQ).

We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Charles River.